Samuel Whiting insider trades
Open-market stock purchases and sales by Samuel Whiting, Chief Medical Officer at Tempest Therapeutics, Inc, from SEC Form 4 filings since Jun 25, 2021.
Track record: 0% of 2 scored buys are up 5% or more since purchase, averaging -57%.
Recent trades
No open-market trades in the last 12 months.
Companies traded
- TPST Tempest Therapeutics, Inc: 2 buys, last Jan 2, 2025